Trial of Intravesical Measles Virotherapy in Patients With Bladder Cancer Who Are Undergoing Radical Cystectomy

• ClinicalTrials.gov Identifier: NCT03171493
• Recruitment Status: Active, not recruiting
• First Posted: May 31, 2017
• Last Update Posted: May 8, 2023
• Sponsor: Vyriad, Inc.
• Collaborator: Mayo Clinic
• Information provided by (Responsible Party): Vyriad, Inc.

Study Description

Brief Summary:

This is a Phase 1 study designed to test the tolerability and feasibility of intravesical therapy with an attenuated Measles virus (MV-NIS) in patients with urothelial carcinoma who are undergoing radical cystectomy but are ineligible or do not desire neoadjuvant chemotherapy.

Condition or disease	Intervention/treatment	Phase
Urothelial Carcinoma	Biological: MV-NIS	Phase 1

Detailed Description:

Study VYR-MV1-102 is a Phase 1 study designed to determine the tolerability, feasibility and preliminary efficacy of attenuated MV-NIS virus after neoadjuvant intravesical administration prior to RC in patients with UC who are ineligible for current neoadjuvant chemotherapy.

Investigators will use a novel adaptive trial design that varies the time between TURBT, virus administration and RC.

Currently, intravesical administration of BCG is delayed four to six weeks after TURBT to reduce the likelihood of systemic BCG absorption and BCG sepsis. Given this clinical safety precedent, Investigators propose initial patients be treated within one week of RC to maximize the time between TURBT and MV-NIS administration.

Subsequent patients will be treated earlier before RC (up to 29 days prior), thereby reducing the interval between TURBT and virus administration to maximize the treatment duration before RC. An expansion cohort will also be used to test the feasibility, tolerability and efficacy of two repeat MV-NIS doses prior to RC. MV-NIS has been proven safe at a dose of 1x1011 TCID50 intravenously in patients lacking MV immunity (Russell 2014), which allays concern for systemic toxicity after intravesical administration even if post-TURBT administration results in systemic MV-NIS absorption.

Pathologic downstaging and CR (assessed by T0 rate) at surgery are secondary endpoints, designed to give an early indication of efficacy potential. This will facilitate future virotherapy strategies targeting replicative tumor destruction and stimulation of systemic anti-tumor immunity as possible strategies for neoadjuvant and bladder-sparing therapy.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 8 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Neoadjuvant Intravesical NIS Measles Virus (MV-NIS) in Patients Undergoing Cystectomy for Urothelial Carcinoma But Ineligible for Neoadjuvant Cisplatin-based Chemotherapy
• Actual Study Start Date: July 20, 2018
• Estimated Primary Completion Date: May 30, 2023
• Estimated Study Completion Date: May 30, 2023

Arms and Interventions

Arm	Intervention/treatment
Experimental: Intravesical MV-NIS therapy prior to radical cystectomy; MV-NIS will be administered via intravesical instillation as a single dose on Day 1 (7, 14, 21 or 28 days before cystectomy) or two doses on Day 1 and 15 (14 and 28 days before cystectomy).	Biological: MV-NIS; Attenuated measles virus encoding NIS (MV-NIS)

Outcome Measures

Primary Outcome Measures :

1. Number of participants with intravesical MV-NIS treatment related adverse events (NCI CTCAE; Version 4.03) [ Time Frame: 30 days after cystectomy ]
   Assessment of safety and toxicity of intravesical MV-NIS administration in patients with Urothelial Carcinoma undergoing cystectomy

Secondary Outcome Measures :

1. Pathologic staging at time of cystectomy following intravesical MV-NIS therapy [ Time Frame: Measured in bladder specimen following cystectomy (up to 29 days following MV-NIS administration) ]
   Preliminary assessment of antitumor efficacy of intravesical MV-NIS therapy
2. pT0 rate at time of cystectomy following intravesical MV-NIS therapy [ Time Frame: Measured in bladder specimen following cystectomy (up to 29 days following MV-NIS administration) ]
   Preliminary assessment of antitumor efficacy of intravesical MV-NIS therapy

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Diagnosis of Urothelial carcinoma (UC) of the bladder, with histologic confirmation of primary UC pathology; indication for Radical cystectomy (RC); ineligibility for platinum-based neoadjuvant chemotherapy
• ECOG Performance Status (PS) 0 or 1.
• Ability to provide informed consent.
• Willingness to comply with all required protocol procedures including providing biologic specimens and returning to the clinical study site for follow up visits.
• Performance status sufficient to undergo RC (in the opinion of the enrolling urologist) including adequate hematological, liver and kidney function
• Must be willing to implement contraception throughout study and for 30 days following RC.

Exclusion Criteria:

• Variant UC pathology including but not limited to micropapillary, signet ring,sarcomatoid, and clear cell variants.
• Patients with any other prior malignancy are not allowed except for the following: History of or concurrent non-invasive UC involving a portion of urinary tract outside of the bladder; Adequately treated basal cell or squamous cell skin cancer; In situ cervical cancer; Adequately treated Stage I or II cancer from which the patient is currently incomplete remission or other cancer from which the patient has been disease-free for 2 years.
• Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways.
• Any of the following prior therapy: Chemotherapy ≤ 3 weeks prior to registration. Biologic therapy ≤ 4 weeks prior to registration. Radiation therapy ≤ 3 weeks prior to registration
• Other concurrent investigational therapy (utilized for a non-FDA-approved indication and in the context of a research investigation).
• Pregnant women.
• Nursing women.
• Men or women of childbearing potential who are unwilling to employ adequate contraception during treatment and 8 weeks following the completion of study drug treatment.
• Allergy to measles vaccine or history of severe reaction to prior measles vaccination.
• History of organ transplantation.

Contacts and Locations

Locations

United States, Florida

University of Miami

Miami, Florida, United States, 33136

United States, Louisiana

Ochsner Health

New Orleans, Louisiana, United States, 70121

United States, Minnesota

Mayo Clinic

Rochester, Minnesota, United States, 55905

Sponsors and Collaborators

Vyriad, Inc.

Mayo Clinic

Investigators

• Study Director: Alice Bexon, MD; CMO - Medical Monitor

More Information

• Responsible Party: Vyriad, Inc.
• ClinicalTrials.gov Identifier: NCT03171493
• Other Study ID Numbers: VYR-MV1-102
• First Posted: May 31, 2017
• Last Update Posted: May 8, 2023
• Last Verified: May 2023

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Vyriad, Inc.:

Bladder cancer; TURBT; Radical cystectomy; BCG; Muscle Invasive Bladder Cancer; Intravesical; chemotherapy for bladder cancer; Oncolytic

Additional relevant MeSH terms:

Carcinoma; Carcinoma, Transitional Cell; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms